Companies ›Healthcare ›CELU.O

CELU.O — NASDAQ Diversified Pharmaceuticals

Celularity Inc

$0,66

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

19,1M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-230,9 %

ROE

241,0 %

Net margin

-345,4 %

Debt / equity

—

Beta

—

52w range

—

Volume

1,2k

Day range

$0,91–$0,98

Prev close

$0,90

Open

$0,91

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Celularity Inc is a biotechnology company focused on developing cell therapy products for oncology and women's health, primarily generating revenue through research and development partnerships and product sales.

Business. Celularity Inc (CELU.O) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target6,00

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

6,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

241,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CELU.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CELU.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Celularity Inc (CELU.O) is a healthcare company operating in the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Celularity operates with a negative total equity of -$38.06 million and a cash and equivalents balance of $6.18 million, indicating a liquidity risk as its cash reserves are insufficient to cover its operating losses of -$61.31 million. The company's market capitalization of $26.27 million is significantly lower than its enterprise value to revenue ratio of 0.76, suggesting a low valuation relative to its revenue.

Profitability metrics show a return on equity of 2.41%, which is below the typical thresholds for pharmaceutical companies, indicating weak returns relative to its equity base. The company's operating margin is negative, with operating income of -$61.31 million on revenue of $26.55 million, reflecting poor operational efficiency.

Celularity's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risks. However, the company's reliance on a limited number of partnerships and product candidates suggests a high concentration risk in its business model.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. Analysts have assigned a mean price target of $6.00, which is significantly higher than the current market price of $0.91, suggesting potential upside if the company can achieve profitability or secure additional funding.

Celularity faces low liquidity and dilution risks based on the absence of immediate filing-based flags. However, the company's negative net income of -$91.72 million and operating cash flow of -$13.25 million indicate a need for external financing, which could lead to future dilution.

Recent events include the publication of financial results and analyst estimates, but no significant corporate actions or regulatory developments were reported in the available data. The company's ongoing research and development activities are likely to be a key focus for future growth.

Key takeaways

Celularity has a negative equity position and insufficient cash reserves to cover its operating losses, indicating a liquidity risk.
The company's return on equity is low, suggesting weak profitability relative to its equity base.
Analysts have assigned a mean price target significantly higher than the current market price, indicating potential upside if the company can achieve profitability.
Celularity's revenue is not segmented, making it difficult to assess geographic or product concentration risks.
The company's negative net income and operating cash flow suggest a need for external financing, which could lead to future dilution.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,66

Market cap

$26.3M

Enterprise valueⓘ

$20.1M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

$6.2M

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

2.4%

Cash conversionⓘ

14.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Cell & Gene Therapies—

low · business_description · 2026-07-04

Contract Manufacturing Services—

low · business_description · 2026-07-04

Tissue & Cell Products—

low · business_description · 2026-07-04

Business relationships

Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

Customers2

ANON:CUST:CELU.O:P12ANON:CUST:CELU.O:P12Customer88%Source ↗

ANON:CUST:CELU.O:P21ANON:CUST:CELU.O:P21Customer88%Source ↗

Supply chain

Vendors → CELU ↔ Partners → Customers · click any node to drill

2 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-07-04

Peer comparison

Peer comparison8 peers · vs CELU · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

-460,2 vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

-195,2 vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

-296,9 vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

-226,8 vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

-233,5 vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price target$6,00 · Median $6,00

Low $6,00High $6,00

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$6,00

Mean$6,00

Median$6,00

High$6,00

Spot$0,66

+808.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-230,9 %Bottom quartile

Net Margin-345,4 %Bottom quartile

ROE241,0 %Best in class

D/E0,00Above median

Cash Conv0,14Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 5 512 680 sh3 exercises · 4 grants10 insiders

Barach Daniele Wolf10% owner · Convertible Notes → Class A Common StockDisposed 1 204 819 @ $1,66other · 2026-06-19
Barach Daniele Wolf10% owner · Warrants → Class A Common StockDisposed 839 160 @ $2,00other · 2026-06-19
Philip & Daniele Barach Family Trust10% owner · Convertible Notes → Class A Common StockDisposed 1 204 819 @ $1,66other · 2026-06-19
Philip & Daniele Barach Family Trust10% owner · Warrants → Class A Common StockDisposed 839 160 @ $2,00other · 2026-06-19
Barach Philip Alan10% owner · Convertible Notes → Class A Common StockDisposed 1 204 819 @ $1,66other · 2026-06-19
Barach Philip Alan10% owner · Warrants → Class A Common StockDisposed 839 160 @ $2,00other · 2026-06-19
Hariri Robert JDirector, Chief Executive Officer · Restricted Stock Units → Class A Common StockDisposed 3 281exercise · 2026-04-13
Haines John RSenior Exec Vice President · Restricted Stock Units → Class A Common StockDisposed 1 641exercise · 2026-04-13
Brigido StephenPres., Functional Regeneration · Restricted Stock Units → Class A Common StockDisposed 821exercise · 2026-04-13
Parks Diane L.Director · Stock Options → Class A Common StockAcquired 156 250 @ $1,20grant · 2025-12-29
Ling Geoffrey M.D.Director · Stock Options → Class A Common StockAcquired 156 250 @ $1,20grant · 2025-12-29
LeVien VincentDirector · Stock Options → Class A Common StockAcquired 156 250 @ $1,20grant · 2025-12-29
Diamandis PeterDirector · Stock Options → Class A Common StockAcquired 156 250 @ $1,20grant · 2025-12-29

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity

Source documents

Celularity Inc Market data — financials · 2026-05-27
Celularity Inc Market data — analyst estimates · 2026-05-27

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Bob J. HaririChairman of the Board, Chief Executive Officer

Insider activity

Mixed / flat0 buys · 0 sellsnet $07 insiders · last 365d

Haines John RSenior Exec Vice President · Class A Common StockOther 1 641 · 2026-04-13
Hariri Robert JDirector, Chief Executive Officer · Class A Common StockOther 3 281 · 2026-04-13
Hariri Robert JDirector, Chief Executive Officer · Class A Common StockOther 1 182 @ $1,28$2K · 2026-04-13
Haines John RSenior Exec Vice President · Class A Common StockOther 583 @ $1,28$746 · 2026-04-13
Brigido StephenPres., Functional Regeneration · Class A Common StockOther 821 · 2026-04-13
Brigido StephenPres., Functional Regeneration · Class A Common StockOther 268 @ $1,28$343 · 2026-04-13
Ling Geoffrey M.D.Director · Class A Common StockOther 19 231 · 2026-01-12
LeVien VincentDirector · Class A Common StockOther 28 847 · 2026-01-12
Diamandis PeterDirector · Class A Common StockOther 20 385 · 2026-01-12
Parks Diane L.Director · Class A Common StockOther 30 000 · 2026-01-12
LeVien VincentDirector · Class A Common StockOther 125 000 · 2025-12-29
Ling Geoffrey M.D.Director · Class A Common StockOther 125 000 · 2025-12-29
Parks Diane L.Director · Class A Common StockOther 125 000 · 2025-12-29
Diamandis PeterDirector · Class A Common StockOther 125 000 · 2025-12-29
Diamandis PeterDirector · Class A Common StockOther 67 416 · 2025-12-19
Ling Geoffrey M.D.Director · Class A Common StockOther 67 416 · 2025-12-19
Parks Diane L.Director · Class A Common StockOther 67 416 · 2025-12-19
LeVien VincentDirector · Class A Common StockOther 3 699 · 2025-11-19
Ling Geoffrey M.D.Director · Class A Common StockOther 44 379 · 2025-11-19
Diamandis PeterDirector · Class A Common StockOther 47 042 · 2025-11-19
Parks Diane L.Director · Class A Common StockOther 61 539 · 2025-11-19

Short positioning

419.5Kshares short+1.5% vs prior

2.85days to cover

9.6%short of daily vol

3.9Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CELU.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorCustomers

Evidence & claims

From filings & derived data

Debt-to-equity (FY 2025-12-31): -3.82xDerived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -107.1%Derived (calculated)
Net margin (FY 2025-12-31): -345.4%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -19.1%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -58.4%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -59.8%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -51.0%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -13.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -36.0%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 33.9%Derived (calculated)
Return on equity (FY 2025-12-31): 241.0%Derived (calculated)
Return on assets (FY 2025-12-31): -85.5%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -36.0%Derived (calculated)
Current ratio (FY 2025-12-31): 0.15xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 736.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -530.7%Derived (calculated)
Cash & equivalents (annual): USD 6.17MSEC XBRL filing
Shareholders' equity (annual): USD -38.06MSEC XBRL filing
Operating income (annual): USD -61.31MSEC XBRL filing
Net income (annual): USD -91.72MSEC XBRL filing
Revenue (annual): USD 26.55MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -4SEC XBRL filing
Shares outstanding (annual): 28.84MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-19 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative

2026-06-19INSIDERPhilip & Daniele Barach Family Trust disposed of 1.20M sh Convertible Notes — 10% owner

2026-06-19INSIDERPhilip & Daniele Barach Family Trust disposed of 839.2k sh Warrants — 10% owner

2026-06-19INSIDERBarach Philip Alan disposed of 1.20M sh Convertible Notes — 10% owner

2026-06-19INSIDERBarach Philip Alan disposed of 839.2k sh Warrants — 10% owner

2026-06-19INSIDERBarach Daniele Wolf disposed of 1.20M sh Convertible Notes — 10% owner

2026-06-19INSIDERBarach Daniele Wolf disposed of 839.2k sh Warrants — 10% owner

2026-06-12FILING8-K filing →

2026-06-03FILING8-K filing →

2026-05-28FILING8-K filing →

2026-04-30FILING10-K filing →

2026-04-21FILING8-K filing →

2026-04-13 00:00 UTCINSIDER9 insider transactions — 2026-04 3 derivative

2026-04-13INSIDERHaines John R transacted 1.6k sh Class A Common Stock — Senior Exec Vice President

2026-04-13INSIDERHariri Robert J transacted 3.3k sh Class A Common Stock — Director, Chief Executive Officer

2026-04-13INSIDERHariri Robert J transacted 1.2k sh Class A Common Stock — Director, Chief Executive Officer ~$2k

2026-04-13INSIDERHaines John R transacted 583 sh Class A Common Stock — Senior Exec Vice President ~$1k

2026-04-13INSIDERBrigido Stephen transacted 821 sh Class A Common Stock — Pres., Functional Regeneration

2026-04-13INSIDERBrigido Stephen transacted 268 sh Class A Common Stock — Pres., Functional Regeneration ~$0k

2026-04-13INSIDERHariri Robert J disposed of 3.3k sh Restricted Stock Units — Director, Chief Executive Officer

2026-04-13INSIDERHaines John R disposed of 1.6k sh Restricted Stock Units — Senior Exec Vice President

2026-04-13INSIDERBrigido Stephen disposed of 821 sh Restricted Stock Units — Pres., Functional Regeneration

2026-03-10FILING8-K filing →

2026-03-05FILING8-K filing →

2026-01-21FILING8-K filing →

2026-01-12 00:00 UTCINSIDER4 insider transactions — 2026-01

2026-01-12INSIDERLing Geoffrey M.D. transacted 19.2k sh Class A Common Stock — Director

2026-01-12INSIDERLeVien Vincent transacted 28.8k sh Class A Common Stock — Director

2026-01-12INSIDERDiamandis Peter transacted 20.4k sh Class A Common Stock — Director

2026-01-12INSIDERParks Diane L. transacted 30.0k sh Class A Common Stock — Director

2026-01-08FILING424B3 filing →

2025-12-31FILINGS-1 filing →

2025-12-30FILING424B3 filing →

2025-12-29 00:00 UTCINSIDER11 insider transactions — 2025-12 4 derivative

2025-12-29INSIDERLeVien Vincent transacted 125.0k sh Class A Common Stock — Director

2025-12-29INSIDERLing Geoffrey M.D. transacted 125.0k sh Class A Common Stock — Director

2025-12-29INSIDERParks Diane L. transacted 125.0k sh Class A Common Stock — Director

2025-12-29INSIDERDiamandis Peter transacted 125.0k sh Class A Common Stock — Director

2025-12-29INSIDERDiamandis Peter acquired 156.2k sh Stock Options — Director

Showing the 40 most recent of 53 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread